{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T16:44:20Z","timestamp":1782492260266,"version":"3.54.5"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s12029-025-01271-3","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T21:13:59Z","timestamp":1752614039000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Prognostic Significance of Circulating Tumor DNA Mutations in Gastrointestinal Stromal Tumors: A Systematic Review and Meta-analysis Based on Time-To-Event Data"],"prefix":"10.1007","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-8707-4823","authenticated-orcid":false,"given":"Gustavo Tadeu Freitas Uch\u00f4a","family":"Matheus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7032-8167","authenticated-orcid":false,"given":"Danilo Monteiro","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9126-0821","authenticated-orcid":false,"given":"Ana Luiza Rocha Soares","family":"Menegat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5703-1687","authenticated-orcid":false,"given":"Brenda Luana Rocha Soares","family":"Menegat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2008-2777","authenticated-orcid":false,"given":"Isabela Junger Meirelles","family":"Aguiar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4511-4801","authenticated-orcid":false,"given":"Pedro Henrique","family":"de Souza Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4872-234X","authenticated-orcid":false,"given":"Rommel Mario Rodr\u00edguez","family":"Burbano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0623-8135","authenticated-orcid":false,"given":"Francisco Cezar Aquino","family":"de Moraes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,15]]},"reference":[{"issue":"83","key":"1271_CR1","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/S0140-6736(13)60106-3","volume":"382","author":"H Joensuu","year":"2013","unstructured":"Joensuu H, Hohenberger P, Corless CL. Gastrointestinal stromal tumour. Lancet. 2013;382(83):973\u201383.","journal-title":"Lancet"},{"key":"1271_CR2","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1097\/MOG.0000000000000584","volume":"35","author":"G Mantese","year":"2019","unstructured":"Mantese G. Gastrointestinal stromal tumor: epidemiology, diagnosis, and treatment. Curr Opin Gastroenterol. 2019;35:555\u20139.","journal-title":"Curr Opin Gastroenterol"},{"key":"1271_CR3","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.canep.2015.10.031","volume":"40","author":"K S\u00f8reide","year":"2016","unstructured":"S\u00f8reide K, Sandvik OM, S\u00f8reide JA, Giljaca V, Jureckova A, Bulusu VR. Global epidemiology of gastrointestinal stromal tumours (GIST): a systematic review of population-based cohort studies. Cancer Epidemiol. 2016;40:39\u201346.","journal-title":"Cancer Epidemiol"},{"key":"1271_CR4","doi-asserted-by":"publisher","first-page":"4540","DOI":"10.3390\/ijms21124540","volume":"21","author":"D Foong","year":"2020","unstructured":"Foong D, Zhou J, Zarrouk A, Ho V, O\u2019Connor MD. Understanding the biology of human interstitial cells of Cajal in gastrointestinal motility. Int J Mol Sci. 2020;21:4540.","journal-title":"Int J Mol Sci"},{"key":"1271_CR5","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2217\/fon-2016-0192","volume":"13","author":"Z Szucs","year":"2017","unstructured":"Szucs Z, Thway K, Fisher C, Bulusu R, Constantinidou A, Benson C, et al. Molecular subtypes of gastrointestinal stromal tumors and their prognostic and therapeutic implications. Future Oncol. 2017;13:93\u2013107.","journal-title":"Future Oncol"},{"key":"1271_CR6","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13045-020-01026-6","volume":"14","author":"CM Kelly","year":"2021","unstructured":"Kelly CM, Gutierrez Sainz L, Chi P. The management of metastatic GIST: current standard and investigational therapeutics. J Hematol Oncol. 2021;14:2.","journal-title":"J Hematol Oncol"},{"key":"1271_CR7","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13045-022-01351-y","volume":"15","author":"M Nikanjam","year":"2022","unstructured":"Nikanjam M, Kato S, Kurzrock R. Liquid biopsy: current technology and clinical applications. J Hematol Oncol. 2022;15:131.","journal-title":"J Hematol Oncol"},{"key":"1271_CR8","doi-asserted-by":"publisher","first-page":"3600","DOI":"10.3390\/cancers13143600","volume":"13","author":"JJ Adashek","year":"2021","unstructured":"Adashek JJ, Janku F, Kurzrock R. Signed in blood: circulating tumor DNA in cancer diagnosis, treatment and screening. Cancers (Basel). 2021;13:3600.","journal-title":"Cancers (Basel)"},{"key":"1271_CR9","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.3390\/cancers12092361","volume":"12","author":"R Agashe","year":"2020","unstructured":"Agashe R, Kurzrock R. Circulating tumor cells: from the laboratory to the cancer clinic. Cancers (Basel). 2020;12:2361.","journal-title":"Cancers (Basel)"},{"key":"1271_CR10","doi-asserted-by":"publisher","first-page":"4342","DOI":"10.1200\/JCO.2003.04.190","volume":"21","author":"MC Heinrich","year":"2003","unstructured":"Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003;21:4342\u20139.","journal-title":"J Clin Oncol"},{"key":"1271_CR11","doi-asserted-by":"publisher","first-page":"4854","DOI":"10.1158\/1078-0432.CCR-13-0765","volume":"19","author":"J Maier","year":"2013","unstructured":"Maier J, Lange T, Kerle I, Specht K, Bruegel M, Wickenhauser C, et al. Detection of mutant free circulating tumor DNA in the plasma of patients with gastrointestinal stromal tumor harboring activating mutations of CKIT or PDGFRA. Clin Cancer Res. 2013;19:4854\u201367.","journal-title":"Clin Cancer Res"},{"key":"1271_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2023.100959","volume":"48","author":"G Calderillo-Ru\u00edz","year":"2024","unstructured":"Calderillo-Ru\u00edz G, P\u00e9rez-Yepez EA, Garc\u00eda-G\u00e1mez MA, Millan-Catalan O, D\u00edaz-Romero C, Ugalde-Silva P, et al. Genomic profiling in GIST: implications in clinical outcome and future challenges. Neoplasia. 2024;48: 100959.","journal-title":"Neoplasia"},{"key":"1271_CR13","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1200\/JCO.2014.57.4970","volume":"33","author":"H Joensuu","year":"2015","unstructured":"Joensuu H, Rutkowski P, Nishida T, Steigen SE, Brabec P, Plank L, et al. KIT and PDGFRA mutations and the risk of GI stromal tumor recurrence. J Clin Oncol. 2015;33:634\u201342.","journal-title":"J Clin Oncol"},{"key":"1271_CR14","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1002\/ijc.32282","volume":"145","author":"S Jilg","year":"2019","unstructured":"Jilg S, Rassner M, Maier J, Waldeck S, Kehl V, Follo M, et al. Circulating cKIT and PDGFRA DNA indicates disease activity in Gastrointestinal Stromal Tumor (GIST). Int J Cancer. 2019;145:2292\u2013303.","journal-title":"Int J Cancer"},{"key":"1271_CR15","unstructured":"Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6:224ra24."},{"key":"1271_CR16","doi-asserted-by":"publisher","unstructured":"Nguyen Hoang V-A, Nguyen N, Le DN, Nguyen VS, Nguyen Thi HG, Vu HT, et al. Real-world utilization and performance of circulating tumor DNA monitoring to predict recurrence in solid tumors. JCO Oncology Advances [Internet]. 2025 [cited 2025 Jun 13];e2400084. Available from: https:\/\/ascopubs.org\/doi\/https:\/\/doi.org\/10.1200\/OA-24-00084","DOI":"10.1200\/OA-24-00084"},{"key":"1271_CR17","doi-asserted-by":"crossref","unstructured":"Bach S, Sluiter NR, Beagan JJ, Mekke JM, Ket JCF, van Grieken NCT, et al. Circulating tumor DNA analysis: clinical implications for colorectal cancer patients. A systematic review. JNCI Cancer Spectr. 2019;3:pkz042.","DOI":"10.1093\/jncics\/pkz042"},{"key":"1271_CR18","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/nm.3511","volume":"20","author":"AR Thierry","year":"2014","unstructured":"Thierry AR, Mouliere F, El Messaoudi S, Mollevi C, Lopez-Crapez E, Rolet F, et al. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. Nat Med. 2014;20:430\u20135.","journal-title":"Nat Med"},{"key":"1271_CR19","doi-asserted-by":"publisher","first-page":"1566750","DOI":"10.3389\/fonc.2025.1566750","volume":"15","author":"X Zhao","year":"2025","unstructured":"Zhao X, Hou S, Hao R, Zang Y, Song D. Prognostic significance of circulating tumor DNA detection and quantification in cervical cancer: a systematic review and meta-analysis. Front Oncol. 2025;15:1566750.","journal-title":"Front Oncol"},{"key":"1271_CR20","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1186\/s12885-024-13116-6","volume":"24","author":"R Yang","year":"2024","unstructured":"Yang R, Li T, Zhang S, Shui C, Ma H, Li C. The effect of circulating tumor DNA on the prognosis of patients with head and neck squamous cell carcinoma: a systematic review and meta-analysis. BMC Cancer. 2024;24:1434.","journal-title":"BMC Cancer"},{"key":"1271_CR21","doi-asserted-by":"crossref","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ [Internet]. 2021 [cited 2025 Feb 18];372:n71. Available from: https:\/\/www.bmj.com\/content\/372\/bmj.n71","DOI":"10.1136\/bmj.n71"},{"key":"1271_CR22","doi-asserted-by":"publisher","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan\u2014a web and mobile app for systematic reviews. Systematic Reviews [Internet]. 2016 [cited 2025 Apr 7];5:210. Available from: https:\/\/doi.org\/10.1186\/s13643-016-0384-4","DOI":"10.1186\/s13643-016-0384-4"},{"key":"1271_CR23","doi-asserted-by":"crossref","unstructured":"Lo CK-L, Mertz D, Loeb M. Newcastle-Ottawa Scale: comparing reviewers\u2019 to authors\u2019 assessments. BMC Med Res Methodol. 2014;14:45.","DOI":"10.1186\/1471-2288-14-45"},{"key":"1271_CR24","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"key":"1271_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-021-01308-8","author":"Liu N, Zhou Y, Lee JJ. IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves. BMC Medical Research Methodology [Internet]","year":"2021","unstructured":"Liu N, Zhou Y, Lee JJ. IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves. BMC Medical Research Methodology [Internet]. [cited 2025 Feb 3];21:111. Available from: 2021. https:\/\/doi.org\/10.1186\/s12874-021-01308-8.","journal-title":"Available from:"},{"key":"1271_CR26","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177\u201388.","journal-title":"Control Clin Trials"},{"key":"1271_CR27","unstructured":"Chapter 10: Analysing data and undertaking meta-analyses [Internet]. [cited 2025 Jun 13]. Available from: https:\/\/training.cochrane.org\/handbook\/current\/chapter-10"},{"key":"1271_CR28","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1002\/ijc.25755","volume":"129","author":"G Arne","year":"2011","unstructured":"Arne G, Kristiansson E, Nerman O, Kindblom L-G, Ahlman H, Nilsson B, et al. Expression profiling of GIST: CD133 is associated with KIT exon 11 mutations, gastric location and poor prognosis. Int J Cancer. 2011;129:1149\u201361.","journal-title":"Int J Cancer"},{"key":"1271_CR29","doi-asserted-by":"publisher","first-page":"5869","DOI":"10.1158\/1078-0432.CCR-08-2480","volume":"15","author":"SE Deprimo","year":"2009","unstructured":"Deprimo SE, Huang X, Blackstein ME, Garrett CR, Harmon CS, Sch\u00f6ffski P, et al. Circulating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib following imatinib failure. Clin Cancer Res. 2009;15:5869\u201377.","journal-title":"Clin Cancer Res"},{"key":"1271_CR30","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1158\/1078-0432.CCR-21-2037","volume":"28","author":"S George","year":"2022","unstructured":"George S, von Mehren M, Fletcher JA, Sun J, Zhang S, Pritchard JR, et al. Phase II Study of Ponatinib in advanced gastrointestinal stromal tumors: efficacy, safety, and impact of liquid biopsy and other biomarkers. Clin Cancer Res. 2022;28:1268\u201376.","journal-title":"Clin Cancer Res"},{"key":"1271_CR31","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1097\/PAS.0000000000000418","volume":"39","author":"S Rossi","year":"2015","unstructured":"Rossi S, Gasparotto D, Miceli R, Toffolatti L, Gallina G, Scaramel E, et al. KIT, PDGFRA, and BRAF mutational spectrum impacts on the natural history of imatinib-naive localized GIST: a population-based study. Am J Surg Pathol. 2015;39:922\u201330.","journal-title":"Am J Surg Pathol"},{"key":"1271_CR32","doi-asserted-by":"publisher","first-page":"6485","DOI":"10.1002\/cam4.3212","volume":"9","author":"Y-Y Shen","year":"2020","unstructured":"Shen Y-Y, Ma X-L, Wang M, Zhuang C, Ni B, Tu L, et al. Exon 11 homozygous mutations and intron 10\/exon 11 junction deletions in the KIT gene are associated with poor prognosis of patients with gastrointestinal stromal tumors. Cancer Med. 2020;9:6485\u201396.","journal-title":"Cancer Med"},{"key":"1271_CR33","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1053\/j.gastro.2006.01.043","volume":"130","author":"J Andersson","year":"2006","unstructured":"Andersson J, B\u00fcmming P, Meis-Kindblom JM, Sihto H, Nupponen N, Joensuu H, et al. Gastrointestinal stromal tumors with KIT exon 11 deletions are associated with poor prognosis. Gastroenterology. 2006;130:1573\u201381.","journal-title":"Gastroenterology"},{"key":"1271_CR34","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1136\/jcp.2007.047043","volume":"61","author":"AL Gomes","year":"2008","unstructured":"Gomes AL, Gouveia A, Capelinha AF, de la Cruz D, Silva P, Reis RM, et al. Molecular alterations of KIT and PDGFRA in GISTs: evaluation of a Portuguese series. J Clin Pathol. 2008;61:203\u20138.","journal-title":"J Clin Pathol"},{"key":"1271_CR35","doi-asserted-by":"publisher","unstructured":"Arshad J, Roberts A, Ahmed J, Cotta J, Pico BA, Kwon D, et al. Utility of circulating tumor DNA in the management of patients with GI stromal tumor: analysis of 243 patients. JCO Precis Oncol [Internet]. 2020 [cited 2025 Apr 7];66\u201373. Available from: https:\/\/ascopubs.org\/doi\/https:\/\/doi.org\/10.1200\/PO.19.00253","DOI":"10.1200\/PO.19.00253"},{"key":"1271_CR36","doi-asserted-by":"publisher","first-page":"3813","DOI":"10.1200\/JCO.2004.05.140","volume":"22","author":"CL Corless","year":"2004","unstructured":"Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol. 2004;22:3813\u201325.","journal-title":"J Clin Oncol"},{"key":"1271_CR37","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S1542-3565(04)00243-5","volume":"2","author":"J-F Emile","year":"2004","unstructured":"Emile J-F, Th\u00e9ou N, Tabone S, Cortez A, Terrier P, Chaumette M-T, et al. Clinicopathologic, phenotypic, and genotypic characteristics of gastrointestinal mesenchymal tumors. Clin Gastroenterol Hepatol. 2004;2:597\u2013605.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1271_CR38","doi-asserted-by":"crossref","unstructured":"Ihle MA, Fassunke J, K\u00f6nig K, Gr\u00fcnewald I, Schlaak M, Kreuzberg N, et al. Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations. BMC Cancer. 2014;14:13.","DOI":"10.1186\/1471-2407-14-13"},{"key":"1271_CR39","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/S0140-6736(04)17098-0","volume":"364","author":"J Verweij","year":"2004","unstructured":"Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay J-Y, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004;364:1127\u201334.","journal-title":"Lancet"},{"key":"1271_CR40","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S0140-6736(12)61857-1","volume":"381","author":"GD Demetri","year":"2013","unstructured":"Demetri GD, Reichardt P, Kang Y-K, Blay J-Y, Rutkowski P, Gelderblom H, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381:295\u2013302.","journal-title":"Lancet"},{"key":"1271_CR41","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1373\/clinchem.2016.257469","volume":"62","author":"N Brychta","year":"2016","unstructured":"Brychta N, Krahn T, von Ahsen O. Detection of KRAS mutations in circulating tumor DNA by digital PCR in Early stages of pancreatic cancer. Clin Chem. 2016;62:1482\u201391.>","journal-title":"Clin Chem"},{"key":"1271_CR42","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1056\/NEJMoa020461","volume":"347","author":"GD Demetri","year":"2002","unstructured":"Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472\u201380.","journal-title":"N Engl J Med"},{"key":"1271_CR43","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.ejca.2007.11.021","volume":"44","author":"S Patel","year":"2008","unstructured":"Patel S, Zalcberg JR. Optimizing the dose of imatinib for treatment of gastrointestinal stromal tumours: lessons from the phase 3 trials. Eur J Cancer. 2008;44:501\u20139.","journal-title":"Eur J Cancer"},{"key":"1271_CR44","doi-asserted-by":"publisher","unstructured":"Clinical activity of BLU-285 in advanced gastrointestinal stromal tumor (GIST). | Journal of Clinical Oncology [Internet]. [cited 2025 Apr 7]. Available from: https:\/\/ascopubs.org\/doi\/https:\/\/doi.org\/10.1200\/JCO.2017.35.15_suppl.11011","DOI":"10.1200\/JCO.2017.35.15_suppl.11011"},{"key":"1271_CR45","doi-asserted-by":"publisher","first-page":"60589","DOI":"10.18632\/oncotarget.16014","volume":"8","author":"K Li","year":"2017","unstructured":"Li K, Cheng H, Li Z, Pang Y, Jia X, Xie F, et al. Genetic progression in gastrointestinal stromal tumors: mechanisms and molecular interventions. Oncotarget. 2017;8:60589\u2013604.","journal-title":"Oncotarget"},{"key":"1271_CR46","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s11864-021-00832-5","volume":"22","author":"D G\u00f3mez-Peregrina","year":"2021","unstructured":"G\u00f3mez-Peregrina D, Garc\u00eda-Valverde A, Pilco-Janeta D, Serrano C. Liquid biopsy in gastrointestinal stromal tumors: ready for prime time? Curr Treat Options Oncol. 2021;22:32.","journal-title":"Curr Treat Options Oncol"},{"key":"1271_CR47","doi-asserted-by":"publisher","unstructured":"Iden CR, Mustafa SM, \u00d8gaard N, Henriksen T, Jensen S\u00d8, Ahlborn LB, et al. Circulating tumor DNA predicts recurrence and survival in patients with resectable gastric and gastroesophageal junction cancer. Gastric Cancer [Internet]. 2025 [cited 2025 Apr 7];28:83\u201395. Available from: https:\/\/doi.org\/10.1007\/s10120-024-01556-9","DOI":"10.1007\/s10120-024-01556-9"},{"key":"1271_CR48","doi-asserted-by":"crossref","unstructured":"George S, Blay J-Y, Chi P, Jones RL, Serrano C, Somaiah N, et al. The INSIGHT study: a randomized, Phase III study of ripretinib versus sunitinib for advanced gastrointestinal stromal tumor with KIT exon 11\u00a0+\u00a017\/18\u00a0mutations. Future Oncol [Internet]. [cited 2025 Jun 13];20:1973\u201382. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC11497949\/","DOI":"10.1080\/14796694.2024.2376521"},{"key":"1271_CR49","unstructured":"Mechahougui H, Hildebrand L, Haberberger J, Sivakumar S, Saiji E, Tukachinsky H, et al. Clinical use of liquid-based comprehensive genomic profiling in gastrointestinal stromal tumors. Laboratory Investigation [Internet]. 2025 [cited 2025 Jun 13];105. Available from: https:\/\/www.laboratoryinvestigation.org\/article\/S0023-6837(25)00026-1\/abstract"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-025-01271-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-025-01271-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-025-01271-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T11:24:04Z","timestamp":1757244244000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-025-01271-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,15]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1271"],"URL":"https:\/\/doi.org\/10.1007\/s12029-025-01271-3","relation":{},"ISSN":["1941-6628","1941-6636"],"issn-type":[{"value":"1941-6628","type":"print"},{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,15]]},"assertion":[{"value":"29 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This systematic review with meta-analysis did not require ethical approval.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"153"}}